You are viewing an incomplete version of our website. Please click to reload the website as full version.

Browse our anti-PLAU (PLAU) Antibodies

Full name:
anti-Plasminogen Activator, Urokinase Antibodies (PLAU)
On www.antibodies-online.com are 331 Plasminogen Activator, Urokinase (PLAU) Antibodies from 30 different suppliers available. Additionally we are shipping PLAU Kits (110) and PLAU Proteins (58) and many more products for this protein. A total of 510 PLAU products are currently listed.
Synonyms:
ATF, BDPLT5, PLAU, QPD, u-PA, uPA, UPAM, URK
list all antibodies Gene Name GeneID UniProt
PLAU 5328 P00749
PLAU 18792 P06869
PLAU 25619  

Show all species

Show all synonyms

Most Popular Reactivities for anti-PLAU (PLAU) Antibodies

Select your species and application

anti-Human PLAU Antibodies:

anti-Mouse (Murine) PLAU Antibodies:

anti-Rat (Rattus) PLAU Antibodies:

All available anti-PLAU Antibodies

Go to our pre-filtered search.

Top referenced anti-PLAU Antibodies

  1. Human Polyclonal PLAU Primary Antibody for EIA, IHC (p) - ABIN360681 : Strausberg, Feingold, Grouse, Derge, Klausner, Collins, Wagner, Shenmen, Schuler, Altschul, Zeeberg, Buetow, Schaefer, Bhat, Hopkins, Jordan, Moore, Max, Wang, Hsieh, Diatchenko, Marusina, Farmer et al.: Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences. ... in Proceedings of the National Academy of Sciences of the United States of America 2002 (PubMed)
    Show all 5 references for ABIN360681

  2. Human Polyclonal PLAU Primary Antibody for IHC (p), ELISA - ABIN360680 : Sperl, Jacob, Arroyo de Prada, Stürzebecher, Wilhelm, Bode, Magdolen, Huber, Moroder: (4-aminomethyl)phenylguanidine derivatives as nonpeptidic highly selective inhibitors of human urokinase. in Proceedings of the National Academy of Sciences of the United States of America 2000 (PubMed)
    Show all 5 references for ABIN360680

  3. Human Monoclonal PLAU Primary Antibody for DB, EIA - ABIN1109451 : Bashkov, Stepanova, Domogatsky: Collagen-targeted antibodies inhibit platelet-dependent thrombosis in vivo. in Thrombosis research 1994 (PubMed)
    Show all 2 references for ABIN1109451

  4. Human Monoclonal PLAU Primary Antibody for ELISA (Capture), EIA - ABIN112281 : Plas, Carroll, Jilch, Mihaly, Vesely, Ulrich, Pflüger, Binder: Analysis of fibrinolytic proteins in relation to DNA ploidy in prostate cancer. in International journal of cancer. Journal international du cancer 1998 (PubMed)

  5. Human Polyclonal PLAU Primary Antibody for WB - ABIN374602 : Morgan, Hill: Human breast cancer cell-mediated bone collagen degradation requires plasminogen activation and matrix metalloproteinase activity. in Cancer cell international 2005 (PubMed)

More Antibodies against PLAU Interaction Partners

Human Plasminogen Activator, Urokinase (PLAU) interaction partners

  1. These studies identify uPA (show PRAP1 Antibodies)-dependent de-repression of vegfr1 (show FLT1 Antibodies) and vegfr2 (show KDR Antibodies) gene transcription through binding to HHEX/PRH (show HHEX Antibodies) as a novel mechanism by which uPA (show PRAP1 Antibodies) mediates the pro-angiogenic effects of VEGF (show VEGFA Antibodies) and identifies a potential new target for control of pathologic angiogenesis.

  2. We concluded that overexpression of MMP-3 (show MMP3 Antibodies) and uPA (show PRAP1 Antibodies), altogether with diminished expression of PAI-1 (show SERPINE1 Antibodies) from metastatic tumors, might be a crucial step towards metastasis in ductal breast cancer.

  3. The up-regulation of uPA (show PRAP1 Antibodies) mRNAs was correlated with high-risk clinicopathological features, including extrathyroid invasion, loss of cellular polarity/cohesiveness, and the BRAF (show BRAF Antibodies)(V600E) mutation.

  4. In contrast to platelet-derived growth factor, all urokinase isoforms induced secretion of MMP-9 (show MMP9 Antibodies) by mesenchymal stromal cells.

  5. Transplantation of uPA (show PRAP1 Antibodies) gene modified mesenchymal stem cells suppressed liver fibrosis and ameliorated liver function and may be a new approach to treating liver fibrosis

  6. ApaL1 and Taq1 single nucleotide polymorphisms of the urokinase and VDR (show CYP27B1 Antibodies) genes are associated with recurrent urolithiasis in a Caucasian population.

  7. 1,25D3 works as a modifier of NF-kappaB (show NFKB1 Antibodies)/GPX1 (show GPX1 Antibodies)/uPA (show PRAP1 Antibodies) expression, inhibiting cisplatin-resistance and cell invasive ability of salivary adenoid cystic carcinoma cells

  8. Resveratrol inhibited hypoxia-induced HIF-1alpha (show HIF1A Antibodies) protein expression. Resveratrol also suppressed hypoxiainduced expression of metastatic-related factors, uPA (show PRAP1 Antibodies) and MMP2 (show MMP2 Antibodies).

  9. Significance of the urokinase-type plasminogen activator and its receptor in the progression of focal segmental glomerulosclerosis in clinical and mouse models.

  10. These findings strongly support the use of uPA (show PRAP1 Antibodies)/PAI-1 (show SERPINE1 Antibodies) together with clinic-pathological parameters as an evidence-based, clinically relevant and inexpensive decision tool in the routine of a breast center.

Mouse (Murine) Plasminogen Activator, Urokinase (PLAU) interaction partners

  1. These studies identify uPA-dependent de-repression of vegfr1 (show FLT1 Antibodies) and vegfr2 (show KDR Antibodies) gene transcription through binding to HHEX/PRH (show HHEX Antibodies) as a novel mechanism by which uPA mediates the pro-angiogenic effects of VEGF (show VEGFA Antibodies) and identifies a potential new target for control of pathologic angiogenesis.

  2. Significance of the urokinase-type plasminogen activator and its receptor in the progression of focal segmental glomerulosclerosis in clinical and mouse models.

  3. GM-CSF (show CSF2 Antibodies) and uPA are required for Porphyromonas gingivalis-induced alveolar bone loss in a mouse periodontitis model.

  4. Plau deficiency does not worsen controlled cortical impact-induced brain pathology or epileptogenesis caused by TBI.

  5. we have firstly shown a fundamental mechanism of urokinase system(uPa and uPAR (show PLAUR Antibodies))-dependent regulation of the trajectory of growth and branching of blood vessels in early embryogenesis and in adults during the repair/regeneration of tissues.

  6. Pharmacological inhibition of either uPA or selected MMPs decreased atherosclerosis in transgenic uPA mice.

  7. Study shows that the competitive expression or activity of tPA (show PLAT Antibodies) and/or PAI-1 (show SERPINE1 Antibodies), rather than an altered uPA expression, determines the plasmin (show PLG Antibodies)-mediated Abeta (show APP Antibodies) proteolysis in brains affected by Alzheimer's disease

  8. Porphyromonas gingivalis-derived RgpA-Kgp complex activates the macrophage uPA.

  9. beta-elemene downregulates expression of uPA, uPAR (show PLAUR Antibodies), MMP-2 (show MMP2 Antibodies), and MMP-9 (show MMP9 Antibodies) in a murine intraocular melanoma model

  10. Data indicate that closed head trauma sequentially releases tissue-type plasminogen activator (tPA (show PLAT Antibodies)) followed by delayed synthesis and release of urokinase plasminogen (show PLG Antibodies) activator (uPA) from injured brain.

Rabbit Plasminogen Activator, Urokinase (PLAU) interaction partners

  1. uPA-mediated arterial constriction is a vasomotor process that is mediated by uPA catalytic activity, not by the NH(2)-terminal domains.

Cow (Bovine) Plasminogen Activator, Urokinase (PLAU) interaction partners

  1. Data show that urokinase-type plasminogen activator (uPA) is only expressed in the cumulus cells of immature and in vitro matured cumulus-oocyte complexes (COCs), while uPA receptor (uPAR (show PLAUR Antibodies)) and plasminogen activator inhibitor-1 (PAI-1 (show SERPINE1 Antibodies)) are expressed in both the cumulus cells and the immature and in vitro matured oocytes.

  2. uPA/uPAR (show PLAUR Antibodies) binding is involved in signaling pathways that activate transcription factors that regulate the synthesis of molecules concerned with the arrangement of a particular oviductal microenvironment.

  3. These data indicated that E. coli LPS (show IRF6 Antibodies) led to an increase in u-PA activity and RNA expression of u-PA and u-PAR (show PLAUR Antibodies) in BME-UV1 cells, thus strengthening the role of the PA system during pathological processes.

  4. The plasminogen/plasminogen (show PLG Antibodies) activator/plasmin (show PLG Antibodies) system is activated during gamete interaction and regulates the sperm entry into the oocyte.

  5. stage-dependent regulation of granulosa cell PA and SerpinE2 (show SERPINE2 Antibodies) production, consistent with a role in extracellular matrix remodeling during follicle growth.

Pig (Porcine) Plasminogen Activator, Urokinase (PLAU) interaction partners

  1. The plasminogen/plasminogen (show PLG Antibodies) activator/plasmin (show PLG Antibodies) system is activated during gamete interaction and regulates the sperm entry into the oocyte.

PLAU Antigen Profile

Antigen Summary

This gene encodes a serine protease involved in degradation of the extracellular matrix and possibly tumor cell migration and proliferation. A specific polymorphism in this gene may be associated with late-onset Alzheimer's disease and also with decreased affinity for fibrin-binding. This protein converts plasminogen to plasmin by specific cleavage of an Arg-Val bond in plasminogen. Plasmin in turn cleaves this protein at a Lys-Ile bond to form a two-chain derivative in which a single disulfide bond connects the amino-terminal A-chain to the catalytically active, carboxy-terminal B-chain. This two-chain derivative is also called HMW-uPA (high molecular weight uPA). HMW-uPA can be further processed into LMW-uPA (low molecular weight uPA) by cleavage of chain A into a short chain A (A1) and an amino-terminal fragment. LMW-uPA is proteolytically active but does not bind to the uPA receptor. Alternatively spliced transcript variants encoding different isoforms have been found for this gene.

Alternative names and synonyms associated with PLAU

  • plasminogen activator, urokinase (PLAU) antibody
  • urokinase-type plasminogen activator (CpipJ_CPIJ002131) antibody
  • urokinase-type plasminogen activator (CpipJ_CPIJ006543) antibody
  • urokinase-type plasminogen activator (CpipJ_CPIJ013396) antibody
  • urokinase-type plasminogen activator (CpipJ_CPIJ013623) antibody
  • plasminogen activator, urokinase (Plau) antibody
  • ATF antibody
  • BDPLT5 antibody
  • PLAU antibody
  • QPD antibody
  • u-PA antibody
  • uPA antibody
  • UPAM antibody
  • URK antibody

Protein level used designations for PLAU

urokinase-type plasminogen activator , U-plasminogen activator , uPA , plasminogen activator, urokinase , plasminogen activator, urinary , Urinary plasminogen activator, urokinase , urokinase plasminogen activator preproprotein

GENE ID SPECIES
403426 Canis lupus familiaris
100171578 Pongo abelii
100302501 Ovis aries
6032874 Culex quinquefasciatus
6038214 Culex quinquefasciatus
6046380 Culex quinquefasciatus
6047199 Culex quinquefasciatus
5328 Homo sapiens
18792 Mus musculus
25619 Rattus norvegicus
100008633 Oryctolagus cuniculus
281408 Bos taurus
396424 Gallus gallus
396985 Sus scrofa
Selected quality suppliers for anti-PLAU (PLAU) Antibodies
Did you look for something else?